denileukin diftitox

{{Infobox drug

| Verifiedfields = changed

| verifiedrevid = 477002950

| image =

| width =

| alt =

| caption =

| pronounce =

| tradename = Ontak, others

| Drugs.com = {{drugs.com|monograph|denileukin_diftitox}}

| MedlinePlus = a611024

| DailyMedID = Denileukin diftitox

| pregnancy_AU =

| pregnancy_AU_comment =

| pregnancy_category =

| routes_of_administration = Intravenous

| class = Antineoplastic

| ATC_prefix = L01

| ATC_suffix = XX29

| ATC_supplemental =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_CA_comment =

| legal_DE =

| legal_DE_comment =

| legal_NZ =

| legal_NZ_comment =

| legal_UK =

| legal_UK_comment =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Ontak (denileukin diftitox) Injection for intravenous infusion Initial U.S. Approval: 1999 | website=DailyMed | url=https://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=246788 | access-date=9 August 2024}}https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761312s000lbl.pdf

| legal_EU =

| legal_EU_comment =

| legal_UN =

| legal_UN_comment =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life = 70-80 min

| duration_of_action =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 173146-27-5

| PubChem =

| IUPHAR_ligand = 7044

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank = DB00004

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| UNII_Ref = {{fdacite|changed|FDA}}

| UNII = 25E79B5CTM

| KEGG = D03682

| ChEBI =

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201550

| NIAID_ChemDB =

| PDB_ligand =

| synonyms =

| IUPAC_name = Diphtheria toxin-Interleukin-2 fusion protein

| C=2560 | H=4042 | N=678 | O=799 | S=17

}}

Denileukin diftitox, sold under the brand name Ontak among others, is an anti-cancer medication used for the treatment of adults with T-cell lymphoma. It is an IL2-receptor-directed cytotoxin. It is an engineered protein combining interleukin-2 and diphtheria toxin.{{cite journal | vauthors = Turturro F | title = Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders | journal = Expert Review of Anticancer Therapy | volume = 7 | issue = 1 | pages = 11–7 | date = January 2007 | pmid = 17187516 | doi = 10.1586/14737140.7.1.11 | s2cid = 9028829 }}

Medical uses

Denileukin diftitox is indicated for the treatment of adults with relapsed or refractory stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Adverse effects

The prescription label contains a boxed warning that capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in people receiving denileukin diftitox.

Society and culture

= Legal status =

In 1999, denileukin diftitox was approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma.{{cite journal | vauthors = Manoukian G, Hagemeister F | title = Denileukin diftitox: a novel immunotoxin | journal = Expert Opinion on Biological Therapy | volume = 9 | issue = 11 | pages = 1445–51 | date = November 2009 | pmid = 19817678 | doi = 10.1517/14712590903348135 | s2cid = 23956460 }}

References

External links

{{cite web | title=Denileukin Diftitox (Code C1476) | website=NCI Thesaurus | url=https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI+Thesaurus&code=C1476 }}

Category:Antineoplastic drugs

Category:Diphtheria